Helen K. Chew, M.D.
Vice Chief, Hematology & Oncology
Director, Clinical Breast Cancer Program
Professor of Medicine
To see if Helen K. Chew is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Specialties
Breast Cancer
Hematology/Oncology
Internal Medicine
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Chew believes in high quality, innovative, and compassionate care of her patients. Dr. Chew believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for her patients. Additionally, the availability of clinical trials moves the field of breast cancer treatment forward.
Clinical Interests
Dr. Chew is the leader of the UC Davis Comprehensive Cancer Center clinical breast cancer program. She is responsible for coordinating surgical, medical and radiation oncology services and clinical trials for breast cancer.
Research/Academic Interests
Dr. Chew's research interests involve novel treatments for breast cancer, serum tumor markers, complications of cancer, including thromboembolism, and treatment-related cognitive dysfunction.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.S., Biological Sciences, Stanford University, Stanford CA 1986
Medical School
M.D., University of Texas Health Sciences Center, San Antonio TX 1991
Internship
Internal Medicine, University of Texas Health Sciences Center, San Antonio TX 1991-1994
Residency
Internal Medicine, University of Texas Health Sciences Center, San Antonio TX 1991-1994
Fellowship
Hematology/Oncology, University of Texas Health Sciences Center, San Antonio TX 1995-1998
Fellowship
Molecular Medicine, University of Texas Health Sciences Center, San Antonio TX 1996-2000
UC Davis Department of Internal Medicine Outstanding Clinician Award,
UC Davis Health System Faculty Recognition Certificate of Excellence and Achievement Award, 2007, 2008
Find a Cure Award, South Placer Breast Cancer Endowment, 2007
Joyce Raley Teel Award for outstanding dedication to the cause of breast cancer, 2006
Christine & Helen Landgraf Memorial Award, 2001
For a comprehensive list of Dr. Chew's publications, please click here (opens new window).
Beechinor R, Palumbo A, Chew HK, Arora M. Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022 Feb;7(1). doi:10.1016/j.esmoop.2022.100393.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021 Dec;32(12):1571-1581. doi:10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. PMID:34656740.
Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707. doi:10.1093/jnci/djz215. PMID:31693129.
Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2021 Jan;71(1):34-46. doi:10.3322/caac.21644. Epub 2020 Sep 30. PMID:32997807.
Hausner SH, Bold RJ, Cheuy LY, Chew HK, Daly ME, Davis RA, Foster CC, Kim EJ, Sutcliffe JL. Preclinical development and first-in-human imaging of the integrin a v b 6 with [ 18 F]a v b 6 -binding peptide in metastatic carcinoma. Clin Cancer Res. 2019 Feb 15;25(4):1206-1215. doi:10.1158/1078-0432.CCR-18-2665.
Keegan THM, Kushi LH, Li Q, Brunson A, Chawla X, Chew HK, Malogolowkin M, Wun T. Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. J Cancer Surviv. 2018 Jun;12(3):388-397. doi:10.1007/s11764-018-0678-8. Epub 2018 Feb 9. PMID:29427203.
Parikh M, Galkin M, Brunson A, Keegan T, Chew HK. Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer. Cancer Treat Res Commun. 2018;16:38-44. doi:10.1016/j.ctarc.2018.06.001. Epub 2018 Jun 13. PMID:31299001.
Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi:10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29. PMID:28356425.
Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jul 1;3(7):906-912. doi:10.1001/jamaoncol.2016.6316. PMID:28125763.